Dapagliflozin

Indication

Triple therapy for treating type 2 diabetes (NICE TA418)

NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Green

Brand:

Forxiga®

Nice TA:

418

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Endocrine system

Background

Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.
The LSCMMG recommends dapagliflozin as a 1^st line ““gliflozin””.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Green	Green	Green	Green	Green	Green	Green	Green

What do the colours mean?

Last Updated: 01 - Dec - 2016